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Abstract
In the last decade, optimized treatment for non-small cell lung cancer had lead to improved prognosis, but the overall
survival is still very short. To further understand the molecular basis of the disease we have to identify biomarkers related to
survival. Here we present the development of an online tool suitable for the real-time meta-analysis of published lung
cancer microarray datasets to identify biomarkers related to survival. We searched the caBIG, GEO and TCGA repositories to
identify samples with published gene expression data and survival information. Univariate and multivariate Cox regression
analysis, Kaplan-Meier survival plot with hazard ratio and logrank P value are calculated and plotted in R. The complete
analysis tool can be accessed online at: www.kmplot.com/lung. All together 1,715 samples of ten independent datasets
were integrated into the system. As a demonstration, we used the tool to validate 21 previously published survival
associated biomarkers. Of these, survival was best predicted by CDK1 (p,1E-16), CD24 (p,1E-16) and CADM1 (p = 7E-12) in
adenocarcinomas and by CCNE1 (p = 2.3E-09) and VEGF (p = 3.3E-10) in all NSCLC patients. Additional genes significantly
correlated to survival include RAD51, CDKN2A, OPN, EZH2, ANXA3, ADAM28 and ERCC1. In summary, we established an
integrated database and an online tool capable of uni- and multivariate analysis for in silico validation of new biomarker
candidates in non-small cell lung cancer.
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Introduction
Although lung cancer treatment options have improved
significantly in the last decade leading to better survival for
patients with every stage of the disease, it is still leading cancer
related deaths in the United States with 160 thousand deaths each
year [1]. With approximately 85% of all cases the most common
type of lung cancer is non-small cell lung cancer (NSCLC), which
includes adenocarcinoma, squamous cell carcinoma, large cell
carcinoma, and bronchioloalveolar carcinoma [2]. Similarly to
other cancer entities we can expect new molecular subtypes to
emerge in the future, as it is now well accepted that the light
microscopy based histologic subdivision uses only one of many
phenotypic manifestations of the genetic changes that underlie
lung cancer development [2].
The identification of genes whose altered expression is
associated with survival differences might enclose the knowledge
to pinpoint those which could serve as indicators of the tumor’s
biological state. In essence there are two possible scenarios for this:
such biomarker can either be an individual gene or a signature
comprising a set of genes. While numerous individual genes
associated with survival have been published in the last thirty
years, new microarray-based multigene molecular prognostic
models using genomic signatures have only emerged in the last
ten years [3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19]. A pre-
requisite for the reproducibility of such genomic signatures is the
availability of raw data, which was only ensured by publications of
the last six years [9,10,11,12,13,14,15,16,17,18]. Remarkably, in
two cases not the signature as a whole, but genes as each
individually important prognostic markers have been identified
[15,19].
The initial discovery of a prognostic marker must be followed by
several validation studies. Then, the results of these are usually
synthesized in a meta-analysis including a large number of
preferably more than thousand patients. Here, by uniting relevant
data from several studies, statistical power is increased and more
accurate estimates can be achieved. Several previous meta-
analyses endeavored to perform such a meta-analysis of previous
studies for solitary gene candidates including VEGF [20], MMP9
[21], cyclin E [22], survivin [23] and CDK1 [24].
Here, we integrated available genome-level transcriptomic
datasets and then used this database to perform a meta-analysis
of previously suggested survival associated biomarker-candidates.
We also set up a global portal for such meta-analysis enabling
express validation of new candidates without large-scale bioinfor-
matic effort in an automated framework.
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Materials and Methods
Construction of lung cancer microarray database
We explored the Cancer Biomedical Informatics Grid (caBIG,
http://cabig.cancer.gov/, microarray samples are published in the
caArray project), the Gene Expression Omnibus (GEO, http://
www.ncbi.nlm.nih.gov/geo/) and The Cancer Genome Atlas
(TCGA, http://cancergenome.nih.gov) to identify lung cancer
datasets using the keywords ‘‘lung’’, ‘‘cancer’’, ‘‘small-cell’’,
‘‘NSCLC’’, ‘‘survival’’, ‘‘GPL96’’, ‘‘GPL3921’’ and ‘‘GPL570’’
(and the alternative names of the microarray platforms). The
search was restricted to publications with simultaneously available
microarray gene expression data and published clinical charac-
teristics including survival. To test randomness, a pairwise rank
test was performed for the collected clinical data including age,
sex, smoking history, histology, stage, grade, success of surgery,
radiotherapy and applied chemotherapy for all patients in WinStat
2013. For the pairwise rank test, the samples were first sorted
according to datasets. Then, each sample (‘‘X’’) in the series was
compared with all values which occur later in the list of all samples
(‘‘Y’’) - assuming randomness, the probability of X.Y is 1/2. The
correlations between clinical variables and survival were investi-
gated and Kaplan-Meier plots for these were plotted using
WinStat 2013. Among the different microarray platforms,
Affymetrix HG-U133A (GPL96), HG-U133 Plus 2.0 (GPL570)
and HG-U133A 2.0 (GPL3921) were included, because these are
regularly used and because these arrays have 22,277 probe sets in
common. The use of the same probe sets enables to measure the
same gene with similar accuracy, relative scale and dynamic range.
To avoid potential bias due to array errors, we have performed
a quality check for all arrays. In this, the background (between 19
and 218), the raw Q (between 0.5 and 14), the percentage of
present calls (over 30%), the presence of bioB-/C-/D- spikes, the
GAPDH 39to 59 ratio (below 4.3) and the beta-actin 39 to 59 ratio
(below 18) were checked. The threshold values correspond to the
95% range of the arrays as described previously [25]. Quality
control was not possible for GSE4573 as for this dataset only the
MAS5 normalized data was available. A filtering was added to the
database to exclude potentially biased arrays. Additionally, we
compared all microarray files using the ranked expression of all
genes to spot microarrays re-published in different studies.
Set-up of server for online survival calculation
The unprocessed.CEL files were MAS5 normalized in the R
environment (http://www.r-project.org) using the simpleaffy
library (http://bioinformatics.picr.man.ac.uk/simpleaffy/). We
have selected MAS5 for normalization as it ranked among the
best normalization methods when contrasted to the results of RT-
PCR measurements in our previous study [26]. Moreover, MAS5
can be applied to single arrays, enabling seamless future extensions
of the database. For the complete database, only the common
probes measured in all three array platforms were retained
(n = 22,277). Then, a second scaling normalization was performed
to center the mean expression for each array to 1000 - this
technique can significantly reduce batch effects. Gene expression
and clinical data were integrated using PostgreSQL, an open
source object-relational database system (http://www.postgresql.
org/).
To assess the prognostic value of a gene, each percentile (of
expression) between the lower and upper quartiles were computed
and the best performing threshold was used as the final cutoff in a
univariate Cox regression analysis. Histology, grade, stage, gender
and smoking history can be used in the multivariate analysis.
However, the multivariate analysis uses less patients as the
univariate analysis because not each patients has all clinical
information. Kaplan-Meier survival plot and the hazard ratio with
95% confidence intervals and logrank P value were calculated and
plotted in R using the ‘‘survplot’’ function of the ‘‘survival’’
Bioconductor package. The R script used by the software to
perform the Kaplan-Meier analysis and to identify the best cutoff
is available as R script S1.
The entire computational pathway is made accessible for re-
analysis in a platform independent online available software
running on a Debian Linux (http://www.debian.org) server
powered by Apache (http://www.apache.org). The scripts on
the server-side were developed in PHP, these control the user
interface, the requests and the delivery of the results. The RODBC
package provides a middleware layer between R and the
PostgreSQL database. This platform can be reached over the
internet via http://www.kmplot.com/lung.
Validation of previously published survival associated
biomarkers
A Pubmed search was performed to identify lung cancer
survival associated biomarkers using all combinations of the
keywords ‘‘lung cancer’’, ‘‘NSCLC’’, ‘‘adenocarcinoma’’, ‘‘squa-
mous cell carcinoma’’, ‘‘survival’’, ‘‘gene expression’’, ‘‘signature’’
and ‘‘meta analysis’’. Only studies published in English were
included. Eligibility criteria also included the investigation of the
biomarker in at least 50 patients - biomarkers described in
experimental models only were omitted. For each gene/signature
the exact conditions in which it was identified have been retrieved,
and these have been used as filtering when selecting the patients
for the survival analysis.
To visualize the performance of the various biomarkers in
datasets including different number of patients, we have generated
funnel plots depicting the hazard ratio (and confidence intervals)
on the horizontal axis vs. the sample size on the vertical axis for
each dataset. We also added an option to the online interface to
simultaneously perform the analysis in each of the individual
datasets. Finally, significance was set at p,0.01.
Results
Construction of combined lung cancer microarray
database
We identified all together 1,715 patients, 1,120 in seven GEO
datasets, 133 patients in TCGA and 462 patients in caArray.
There were no samples repeatedly published. One sample
(GSM370984) failed two parameters in the quality control - this
array was excluded from all analyses. Additionally, in 215 arrays
one parameter was out of the 95% range of all arrays - these arrays
can be excluded from analyses by selecting the ‘‘exclude outlier
arrays’’ in the online interface. Overall survival was published for
1,405 patients and time to first progression was published for 764
patients. We have collected age, sex, smoking history, histology,
stage, grade, success of surgery, radiotherapy and applied
chemotherapy for all patients - none of these parameters was
significant in the pairwise rank test indicating random distribution
of the data. A summary of these clinical properties for each dataset
used is presented in Table 1. The survival of the patients stratified
by subtype, gender, smoking history and stage is presented in
Figure 1.
Set-up of online survival analysis platform
We have employed Kaplan-Meier plots to visualize the
association between the gene under investigation and survival.
Before analysis, the patients were filtered using the available
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clinical parameters to include only those patients where the
relevance of the gene is to be assessed. Besides filtering options
specific for clinical parameters, we implemented an algorithm
which includes the use of all percentiles between the lower and
upper quartile to identify the best performing cutoff.
To our knowledge, present development is the very first system
enabling real-time multivariate survival analysis of genes in
available transcriptomic cohorts.
Validation of previously published NSCLC biomarkers
We identified 21 previously published survival associated
individual genes and 7 gene expression signatures (listed in Table
S1). Each of these biomarker candidates were investigated in a
cohort having similar clinical characteristics as the patients in
which they were originally described. For genes measured by
several probe sets on the microarrays, those with the highest
quality were used (high quality: average expression over 500 or
maximal expression over 1000, low quality: average expression
below 100, intermediate: all other probes). In case there were
several high quality probes then the best performing was used. The
analysis results are presented in Table 2 and Figure 2.
Discussion
The importance of cancer biomarkers is highlighted by the
success of the HER2 gene in breast cancer. High HER2
expression was first a marker of worse survival, but the
introduction of targeted anti-HER2 therapy changed the picture:
today HER2 positive patients have an improved prognosis
compared to women with HER2 negative disease [27].
Here, by using an integrated database of ten previously
published transcriptomic datasets, we validated the association
with survival for a set of genes in non-small-cell lung cancer.
Generally, the strongest associations were found for those also
investigated in a previous meta-analysis (VEGF, CCNE1 and
CDK1). For all of these genes higher expression was associated
with shorter survival. With over 5,000 patients, the meta-analysis
for VEGF [20] employed the highest number of patients – our
analysis also confirmed the correlation of VEGF expression and
overall survival in NSCLC patients by both univariate and
multivariate analyses. The importance of VEGF is due to the
availability of targeted agents directly inhibiting its activation.
Interestingly, for one of the genes (CDK1) a previous meta-
analysis actually rejected a correlation between the gene and
survival [24]. In contrast, our results represent a large-scale
independent validation of the gene. In individual genes, only a few
were associated with longer survival when displaying higher
expression – these include CADM1, ANXA3, ADAM28, XIAP
and XAF1. Future therapeutic targeting of these will only be
possible using a different approach than for most genes in which
higher expression actually results in shorter survival.
After surgery, about two-thirds of recurrences for early stage
disease occur at distant sites. Therefore, the eradication of
micrometastases must have a high priority as early as possible. A
previous meta-analysis of all the trials investigating chemotherapy
benefit demonstrated a 5% improvement in overall survival [28].
This survival advantage with chemotherapy was also maintained
at 9 years of follow-up. For these reasons the use of adjuvant
chemotherapy is the current standard of care for patients with
early stage NSCLC. In our analysis system we have integrated the
use of chemotherapy to enable the validation of genes specifically
related to survival in chemotherapy treated patients.
A major etiological factor for lung cancer is cigarette smoking
which accounts for nearly 85% of all cases. Lung cancer
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Table 2. Performance of previously published biomarker candidates associated with survival in non-small-cell lung cancer.
Gene Literature data Meta-analysis results
Symbol Ref. n Method used Cohort Probe ID* n & Cutoff & HR&
p value:
univariate
p value:
multivariate
Genes examined in a meta-analysis
VEGF [20] 5386 IHC, RT-PCR NSCLC 211527_x_at 1404 244 1.9 3.3e-10 ,1e-16
MMP9 [21] 2029 IHC, RT-PCR NSCLC 203936_s_at 1404 1865 1.21 0.012 -
ADE 486 734 1.51 0.02 -
CCNE1 cyclin E [22] 2606 IHC NSCLC 213523_at 1404 276 1.59 2.3e-09 0.0096
ADE 486 167 2.44 4.8e-08# 0.0013
BIRC5 survivin [23] 2703 IHC, FISH RT-PCR NSCLC stage 2 202095_s_at 185 295 1.56 0.077 -
CDC2 CDK1 [24] 2731 IHC, RT-PCR NSCLC 210559_s_at 1404 266 2.56 ,1e-16# 0.0019
Genes identified in original studies
CADM1 [15] 617 Array + IHC ADE 209031_at 486 1793 0.38 7e-12# 0.0001
CEA [33] 97 IHC NSCLC 206199_at 1404 110 1.21 0.02 -
RAD51 [34] 383 IHC NSCLC 205023_at 1404 44 1.4 2.4e-05 0.24
ADE 486 34 1.36 0.046 -
SCC 421 45 1.2 0.18 -
CDKN2A P16 [35] 106 IHC NSCLC 209644_x_at 1404 1382 1.65 1.8e-09 0.12
ADE 486 486 2.23 6.8e-08 0.012
OPN [36] 25 IHC All patients 209875_s_at 1404 4151 1.5 2.8e-06 0.0001
[37] 82 RT-PCR NSCLC surgical
margin neg.
704 4101 1.93 1.5e-06 0.0032
EZH2 [38] 106 IHC NSCLC stage 1 203358_s_at 440 600 2.07 2.6e-06 0.32
IFNAR2 [39] 113 IHC NSCLC PFS 204785_x_at 764 799 1.41 0.0012 0.05
ANXA3 [40] 125 MS, 2D-DIGE ADE 209369_at 486 811 0.49 9.2e-07 0.0093
S100A4 [41] 400 IHC SCC 203186_s_at 421 2844 1.24 0.12 -
ADAM28 [42] 90 ELISA NSCLC 205997_at 1404 143 0.69 8.3e-06 0.003
XIAP [43] 144 IHC NSCLC 206536_s_at 1404 85 0.86 0.071 -
XAF1 [44] 51 RT-PCR SCC 206133_at 421 253 0.72 0.025 -
CD24 [45] 267 IHC ADE 209772_s_at 486 618 2.45 3.6e-10 ,1e–16
ERCC1 [46] 51 RT-PCR NSCLC 203719_at 1404 685 1.65 1.4e-10 ,1e-16
HER2 [47] 83 RT-PCR NSCLC 216836_s_at 1404 898 1.25 0.0057 0.12
CD82 [48] 151 RT-PCR NSCLC 203904_x_at 1404 506 1.27 0.0029 0.09
Gene expression signatures identified using microarrays
139-gene [13] 253 Array NSCLC stage I see Table S1 440 3368.7 3.59 8.9e-16# ,1e-16
59-gene [14] 100 Array NSCLC see Table S1 1404 4038.6 0.66 9.9e-08 0.035
15-gene [10] 133 Array + RT-PCR NSCLC + chemo see Table S1 173 573.7 0.6 0.042 -
50-gene [9] 129 Array + RT-PCR + IHC SCC see Table S1 421 754.3 0.65 0.0016 0.0023
17-gene [11] 91 Array NSCLC see Table S1 1404 618.3 1.27 0.0027 0.48
6-gene [16] 138 Array + RT-PCR NSCLC PFS see Table S1 764 543.5 0.77 0.017 -
38-gene [17] 462 Array ADE see Table S1 468 437.7 0.64 0.0031 0.092
ADE: adenocarcinoma; SCC: squamous cell carcinoma; 2D-DIGE: two-dimensional difference gel electrophoresis; MS: mass spectrometry; n: number of tumor samples
included in the study; *highest quality probe, when several high quality probes then the best performing; # see Figure 2. for the survival plots; & of the univariate
analysis; multivariate: using those two parameters where most data was available (histology and gender for NSCLC, gender and stage for adenocarcinoma and
squamous cell carcinoma). Multivariate analysis was performed only for biomarker candidates significant at p,0.01 in the univariate analysis.
doi:10.1371/journal.pone.0082241.t002
Figure 1. Survival characteristics of the patients included in the database including histology of adenocarcinoma (adeno),
squamous cell carcinoma (SCC) and large cell carcinoma (large), gender, stage (only with overall survival) and smoking history.
doi:10.1371/journal.pone.0082241.g001
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development is similar to other cancer types by involving a
stepwise progression to a malignant transformation driven by the
collective effect of genetic changes induced by inhaled carcinogens
[29]. At the same time, the number of previously never-smoker
lung cancer patients is also increasing [30]. Gathering new insights
into the underlying mechanism and etiological factors in these
patients is necessary to better understand the disease and to
develop new treatment strategies [2]. In our database we had the
smoking history for 1,042 patients (of these 187 never smoker) and
the meta-analysis tool also includes the option to restrict to either
smoker on nonsmoker cohorts of patients. Additional filtering
options include the use of gender (data is available for 1,564
patients) and staging (697 patients). Combinations of these options
enable to validate biomarker candidates in sub-cohorts having a
size not reached by any of the previous individual studies.
Previously, within the directors’ challenge project for lung
adenocarcinoma, the combined use of clinical and gene expression
information performed best for predicting prognosis [17]. The
multivariate analysis in the online software enables to compare
clinical and molecular variables. Unfortunately, not all clinical
information is published for each patient - this significantly limits
the potential of any multivariate analysis including both clinical
and gene expression variables.
We must also mention some issues with meta-analyses that may
undermine their validity - these include biases related to patient
selection, to clinical heterogeneity, to different outcome measures,
to methodological and statistical techniques [31]. One option the
test for biases is plotting the sample size against the effect size as
this is usually skewed and asymmetrical in the presence a bias [32].
Basically, without a bias, the largest variation should be observed
most in the small studies and least in large studies. This is the
concept of the original funnel plot which we employed to
demonstrate the correlation between hazard rates and sample
sizes for two selected genes. We added an analysis option to our
tool to run the computations in each dataset separately to enable
swift construction of such analyses for any gene.
Finally, we have also assessed previously published gene
expression signatures to predict survival. Today, the clinical
application of multigene signatures is still controversial, as many of
them do not outperform prognostication using conventional
parameters. Here, out of seven signatures, two were capable to
predict survival in stage I [13], and in all NSCLC patients [14].
In summary, by utilizing genome-wide microarray datasets
published in the last five years, we have successfully integrated a
large scale database suitable for the in silico validation of biomarker
candidates in non-small cell lung cancer.
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Table S1 List of genes involved in previously published gene
sets.
(XLS)
R Script S1 R script used to generate Kaplan-Meier plots
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